Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026
Source: SeekingAlpha
2026-03-13 08:57:08 ET
Investment Overview
Sutro Biopharma ( STRO ) stock trades at a value of $25 today, following a 1-10 reverse stock split completed in December 2025. The South San Francisco-based biotech's market cap valuation is $406m at the time of writing. Shares are up 115% year-to-date and >160% on a six-month basis....
Read the full article on Seeking Alpha
For further details see:
Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026
Sutro Biopharma Inc.
NASDAQ: STRO
STRO Trading
0.06% G/L:
$39.60 Last:
109,896 Volume:
$43.85 Open:
STRO Latest News
May 14, 2026 04:05:00 pm
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsApril 19, 2026 07:45:00 pm
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026March 23, 2026 04:05:00 pm
Sutro Biopharma Reports Full Year 2025 Financial Results and Business HighlightsSTRO Stock Data
$132,896,188
8,207,042
0.54%
38
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
